A Clinical Trial on the Efficacy of tDCS) in Reducing Alcohol Consumption in Non-abstinent Patients (REDSTIM)

  • End date
    Nov 22, 2022
  • participants needed
  • sponsor
    Centre Hospitalier Universitaire Dijon
Updated on 23 January 2021
psychiatric disorder
alcohol use disorder


The study evaluates the efficacy of 1 week of tDCS (5 sessions) placebo in reducing alcohol consumption within the 24 weeks following the treatment in non-abstinent patients with alcohol use disorders versus placebo.


340 patients are expected and randomized in two groups: 170 patients with active tDCS and 170 patients with placebo tDCS

Visit 1 : Patients will received one daily session (13:20:13) during 5 consecutive days: current flows continuously twice for 13min with a rest interval (no stimulation) of 20 min.

Visit 1 to 7 : Change from baseline to week 24 in Total Alcohol Consumption (TAC) and Number of Heavy Drinking Days (HDD) will be evaluated in each group.

Evaluation on alcohol consumption (daily drinking diary, alcohol craving and severity) and other assessments like mood, quality of life, safety.

The co-primary outcome of change from baseline in total alcohol consumption AND reduction in number of heavy drinking days at 6 months after treatment and its association with tDCS will be analyzed under the intention-to-treat principle using a mixed model repeated measures (8 times).

Condition Alcohol abuse, Alcohol Dependence, Alcohol Use Disorder, Alcohol Use Disorder, Alcohol Dependence
Treatment active tDCS, Placebo tDCS
Clinical Study IdentifierNCT02505126
SponsorCentre Hospitalier Universitaire Dijon
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Patients must have signed and dated the informed consent form
Male and female patients over 18 years of age
Patients who meet at least two criteria for Alcohol Use Disorder as defined in the Diagnostic and statistical Manual of mental disorder (DSM-5)
Patients who are motivated to reduce their alcohol consumption
At least one attempt to achieve abstinence (unsuccessful or relapse) or to reduce alcohol consumption

Exclusion Criteria

Breath-alcohol concentration > 0 milligrams per litre of exhaled air at randomization (visit 1)
< 6 heavy drinking days in the 4 weeks before randomization (European Medicines Agency, 2010; a day with alcohol consumption 60 g for men and 40 g for women)
An average alcohol consumption below medium risk level according to World health Organization (WHO) in the 4 weeks before screening (WHO, 2000; 40g/day for men; 20g/day for women)
More than 3-days abstinence prior to screening and randomization (screening visit and visit 1)
A Revised Clinical Institute Withdrawal Assessment for Alcohol score 10 (indicating the need for medication supported detoxification) at randomization (visit 1)
Concomitant treatment with disulfiram, acamprosate, topiramate, baclofen, naltrexone, and nalmefene (<1 month)
History of pre-delirium tremens and delirium tremens
DSM-5 substance use disorder other than alcohol or nicotine use disorder
Acute psychiatric disorders that have required hospitalisation and/or immediate adjustment of psychotropic medications
Major depression, as defined by Hamilton Depression (HDRS) scale greater than or equal to 24
Recent change in psychotropic medication (< 1 month)
Severe chronic psychiatric disorders including schizophrenia, paranoia and bipolar disorder type I and II
Advanced liver, kidney, cardiac, or pulmonary disease or other acute serious or unstable medical condition that would compromise patient's participation in the study according to physician's judgment
Contra-indications to tDCS: metal in the head, implanted brain medical devices
Women who are pregnant or lactating
Women of childbearing potential with a positive urine -human chorionic gonadotrophin pregnancy test at randomization (visit 1)
Concurrent participation in other trial
Employees of the investigator or trial site
Patients protected by law
Persons who are not covered by national health insurance
Patients, in the opinion of the investigation, not able to complete the TLFB and to complete their daily alcohol consumption in a diary (derived from the TLFB) during the 3 months of the study
Patients who refused to sign "safety" agreement
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note